Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.
- During a recent TechMediaWire Podcast appearance, Justin Hanka outlined MindBio Therapeutics’ progress in developing advanced AI-driven voice analysis technology for drug and alcohol intoxication detection.
- MindBio Therapeutics Corp. says its prediction models are trained using more than 50 million data points collected through years of clinical and behavioral research.
- The company’s initial commercial strategy focuses on workplace safety sectors including mining, aviation, and construction, where impairment-related incidents carry significant operational and regulatory risks.
- Hanka said during the interview that the company’s voice-analysis platform can detect not only alcohol intoxication but also drugs affecting the central nervous system, including cannabis, cocaine, opioids, and psychedelics.
- Management expects live workplace testing deployments to begin later in the second quarter of 2026 as the company transitions from development toward commercial implementation.
- MindBio views its technology as part of a broader AI-driven diagnostics technology capable of supporting future health and wellness applications beyond intoxication monitoring.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, used a recent appearance on the TechMediaWire Podcast to outline how the company plans to commercialize its technology, starting with testing plans as of Q2 this year (https://ibn.fm/HLMKz). During the discussion with podcast host Stuart Smith, MindBio Founder and Chief Executive Officer Justin Hanka described the company’s work using speech analytics and machine learning to identify physiological indicators associated with intoxication through non-invasive voice analysis (https://ibn.fm/BUKfp).
According to Hanka, MindBio has spent several years conducting drug and alcohol research while collecting extensive speech and voice datasets through clinical studies and related programs. As AI and machine-learning systems have improved, the company believes it has developed models capable of…
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
